Detalhe da pesquisa
1.
Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F-DCFPyL test-retest cohort.
Prostate
; 83(6): 547-554, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36632656
2.
Test-retest repeatability of organ uptake on PSMA-targeted 18 F-DCFPyL PET/CT in patients with prostate cancer.
Prostate
; 83(12): 1186-1192, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37211963
3.
High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL.
Mol Imaging
; 2022: 7056983, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35283693
4.
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Prostate
; 82(12): 1176-1185, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35538398
5.
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
Prostate
; 81(6): 326-338, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33636027
6.
Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies.
Oncologist
; 26(7): e1179-e1188, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33904646
7.
Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
J Urol
; 206(3): 623-629, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34003011
8.
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
Prostate
; 80(5): 407-411, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31972048
9.
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.
J Urol
; 204(3): 496-502, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32250727
10.
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
BMC Cancer
; 20(1): 492, 2020 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32487038
11.
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
Nature
; 515(7525): 134-7, 2014 Nov 06.
Artigo
Inglês
| MEDLINE | ID: mdl-25156255
12.
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Prostate
; 79(14): 1597-1603, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31361358
13.
Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
Prostate
; 79(13): 1572-1579, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31389628
14.
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
Invest New Drugs
; 37(5): 1052-1060, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30725389
15.
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
BMC Cancer
; 19(1): 572, 2019 Jun 13.
Artigo
Inglês
| MEDLINE | ID: mdl-31196032
16.
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.
World J Urol
; 37(12): 2623-2629, 2019 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-30191396
17.
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Lancet Oncol
; 19(1): 76-86, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29248236
18.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 373(8): 737-46, 2015 Aug 20.
Artigo
Inglês
| MEDLINE | ID: mdl-26244877
19.
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
J Urol
; 200(5): 956-966, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-29730201
20.
Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer - Playing the Right CARD.
N Engl J Med
; 381(26): 2564-2566, 2019 12 26.
Artigo
Inglês
| MEDLINE | ID: mdl-31881143